Waiv and Daiichi Sankyo Partner on AI Biomarkers
PARIS, France, May 8, 2026 Waiv, the Paris-based artificial intelligence precision medicine company formerly known as Owkin Dx, announced...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
PARIS, France, May 8, 2026 Waiv, the Paris-based artificial intelligence precision medicine company formerly known as Owkin Dx, announced...
Boston, Massachusetts — November 19, 2025 — Beacon Biosignals has announced a multi-year expansion of its strategic collaboration with...
